Evogene Ltd. — Form 6-K Summary
Reporting context: Form 6-K for September 2026, filed by Evogene Ltd., a foreign private issuer. The report states that on September 30, 2026, Evogene announced a Nasdaq extension to regain minimum bid-price compliance.
Key development
- Nasdaq granted Evogene an additional 180-day period, through March 29, 2027, to regain compliance with the minimum bid-price requirement.
- The report does not specify the required bid price, the compliance steps Evogene plans to take, or the consequences if compliance is not restored.
Financial performance and outlook
This filing contains no financial statements or information on revenue, profit, cash flow, margins, debt, liquidity, guidance, or operating performance. It provides no clear value for these items.
Material changes, risks, and unusual items
The Nasdaq extension is the material development disclosed. Failure to regain compliance by the deadline may put the company’s Nasdaq listing at risk; the filing does not detail the potential outcome. The filing says it is incorporated by reference into specified Evogene registration statements.
Important facts for investors to verify
- Review Exhibit 99.1, the referenced press release, for the full details of Nasdaq’s notice and any company response; the exhibit text is not included in the provided filing content.
- Check subsequent company disclosures for progress toward bid-price compliance and any further Nasdaq action.
- Confirm the applicable Nasdaq minimum bid-price requirement and the consequences if Evogene does not meet it by March 29, 2027.